Diagnostic test for 14-3-3 protein

Used for A positive 14-3-3 protein detection in CSF has ~90% sensitivity and specificity for sporadic CJD


You need to login or register to bookmark/favorite this content.

Post author: Dementia Diagnostics Laboratory. Last update: 29/04/2016 at 2:43 pm by Tanya Mitchell.


Dr. Qiao-Xin Li

Phone: +61 3 9035 7243


Service overview

The National Dementia Diagnostics Laboratory (NDDL) located at the Florey Institute of Neuroscience and Mental Health, The University of Melbourne has been in operation since 2013. The NDDL offers NATA accredited diagnostic testing for Alzheimer’s disease and Creutzfeldt-Jakob disease (CJD), the only laboratory in Australia to offer this service. NDDL offers its diagnostic services to the medical community, scientific researchers and the pharmaceutical industry. (NATA/RCPA accreditation #19256).

Additional info

The 14-3-3 protein detection in CSF; a positive result has approximately 90% sensitivity and specificity for sporadic Creutzfeldt Jakob disease (CJD). The 14-3-3 protein is an ante-mortem, non-specific marker of central nervous system neuronal injury or death.
-Klug et al. Creutzfeldt-Jakob disease surveillance in Australia, update to December 2013. Commun Dis Intell Q Rep. 2014; 38(4):E348-55.
-Collins et al, Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 2000; 7:203-208


Capacity: We encourage greater utilisation
Operation: Facility provides the service for you
Access: Access by collaboration, Access by fee for service
Accreditation: ISO 15189